Competent Cells Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Competent Cells Market is segmented by Type (Chemically Competent Cells and Electrocompetent Cells), Application (Protein Expression, Cloning, Biotechnology, and Other Applications), End User (Biopharmaceutical Companies, Contract Research Organizations, and Academic Institutions), and Geography (North America, Asia-Pacific, Europe, Middle East, and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Competent Cells Market Size

Competent Cells Market Summary
Study Period 2021 - 2029
Base Year For Estimation 2023
CAGR 9.40 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Competent Cells Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Competent Cells Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Competent Cells Market Analysis

The competent cells market is expected to register a CAGR of 9.4% over the forecast period.

The COVID-19 pandemic had a significant effect on the competent cells market. The increasing usage of competent cells in the research and development activities for the cell cloning activities of SARS-CoV-2. For example, an article published by Nature Journal in January 2021 reported the construction of a full-length SARS-CoV-2 genome via in-vitro competent cells in order to study the virus in-vitro and in vivo. Such application of competent cells in cloning the virus genome in order to develop appropriate treatments had a significant impact on the growth of the market. In addition, the demand for competent cells is expected to remain intact due to the emergence of a mutant strain of SARS-CoV-2 and to understand their mechanisms as well, thereby contributing to the growth of the market over the forecast period.

Advancements in molecular engineering due to the emergence of new cell technologies in biotechnology industries are augmenting the growth of the market studied. Additionally, increased investments from public and private companies and the development of advanced products are anticipated to boost the market growth in the studied regions. For example, in December 2021, Pfizer announced opening of a new state-of-the-art clinical manufacturing facility in Durham. The facility will expand Pfizer's end-to-end capabilities in gene therapy and builds on the company's existing footprint in North Carolina. The Durham facility is part of a USD 800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer's continued investment in gene therapy. Such increasing investment by various market players for the development of various advanced therapies is also expected to drive the demand for competent cells owing to the high efficacy in various biotechnology procedures, thereby contributing to the growth of the market.

According to an SEU article published in July 2022, venture capitalists in Europe invested nearly over USD 18 billion into European biotech startups. Such high amounts of capital-raising capabilities from major companies are likely to lead to further investment in research and development activities. They are also expected to drive the growth of the market over the forecast period.

However, the very high cost of research and development of competent cells and the market consolidation of a few major players are expected to hamper the market growth over the period.

Competent Cells Market Trends

This section covers the major market trends shaping the Competent Cells Market according to our research experts:

Biotechnology is Expected to Register Good Growth Rate Over the Forecast Period

The biotechnology segment is also projected to witness a notable growth rate due to increasing investments in R&D and the commercialization of proteomics and genomic-based products. Furthermore, the need for advanced product technologies in the treatment of various diseases is projected to bolster the segment's growth. These areas are likely to see renewed interest, due to which demand for competent cells will increase, as they can be used in therapeutic biotechnology research.

In addition, increased funding for studies for biotechnology for the market players and research institutions by various government organizations is also expected to contribute to the growth of the studied segment. For instance, in August 2022, the Minister of Science and Technology announced grants for collaborative biotech initiatives involving India's startups, industry, academic, and research bodies. The participants can avail of grants of INR 10-15 crores (USD 12.08 million) over three years for high-quality research. Similarly, the Biotechnology Ignition Grant Scheme (BIG) was implemented by the Government of India to fund biotech startups with USD 70,000. Such increasing funding for biotechnology is expected to contribute to the demand for competent cells as they are widely used in biotechnology research, thereby fueling segment growth.

Competent Cells Market: Estimated Funding for the Biotechnology Research (in USD Million), United States,2021-2030

North America is Expected to Register Notable Growth in the Market Over the Forecast Period

The North American market is anticipated to hold a majority share of the global competent cells market during the forecast period. The growth is attributed to extensive studies on DNA cloning technologies, increasing biotechnology research, high research and development expenditure in the region, and the presence of key market players.

For example, the article published by NIH in March 2022 mentioned that the funding for biotechnology research in the United States in 2021 was USD 7,847 million and is expected to reach USD 8,104 by 2030. Similarly, the Government of Canada data published in 2022 mentioned that the Government of Canada invested over USD 500 million for four years, starting 2021-2022, to support the bioscience infrastructure in Canada. Such increasing funding activities for the development of various biotechnology research activities involving the vast utilization of competent cells are also expected to contribute to the growth of the market.

Moreover, increasing market players' strategies, such as collaborations, agreements, investments, and others for DNA-based research, is also expected to contribute to the growth of the market. For instance, in May 2022, Avantor agreed with CytovanceBiologics, a contract development and manufacturing organization specializing in plasmid DNA, to manufacture research- and good manufacturing practice (GMP)-grade plasmids for viral vectors and messenger RNA (mRNA)-based vaccines and therapeutics. Also, in January 2022, Alcami, a United States-based pharmaceutical contract development and manufacturing organization (CDMO), is investing USD 10 million to expand its laboratory operation in North Carolina, United States, to enhance its large molecule and cell and gene therapy analytical service offering.

Thus, the rising funding activities for biotechnology research, along with extensive DNA-based studies and market players' strategies, are expected to contribute to the growth of the market in this region.

Competent Cells Market - Growth Rate by Region

Competent Cells Industry Overview

The competent cells market is moderately consolidated with a notable number of market players. Companies are focusing on developing new technologies in cell DNA cloning and broadening the applications of competent cells. The key market players operating in the market include Thermo Fisher Scientific, Merck KGaA, Qiagen, Takara Bio Inc., and New England BioLabs Inc.

Competent Cells Market Leaders

  1. Thermo Fisher

  2. Merck KGaA

  3. New England Biolabs

  4. Takara Bio

  5. Agilent Technologies, Inc.

*Disclaimer: Major Players sorted in no particular order

Competent Cells Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Competent Cells Market News

  • July 2022: Epic-Bio, developing ultra-compact therapies to modulate gene expression in vivo, launched series A financing of USD 55 million.
  • June 2022: RegenxBio launched its new in-house facility in the United States, which will be used to manufacture gene therapies at a commercial scale. The company invested USD 65 million to enable end-to-end control of gene therapy manufacturing at the center.

Competent Cells Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Commercial Demand and Continuous Support From Government and Educational Institutions
    • 4.2.2 Advancements in Cell Technologies in Healthcare
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Research and Development
    • 4.3.2 Growing Market Consolidation and Difficult Market Entry
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Chemically Competent
    • 5.1.2 Electrocompetent
  • 5.2 By Application
    • 5.2.1 Protein Expression
    • 5.2.2 Cloning
    • 5.2.3 Biotechnology
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Biopharmaceutical Companies
    • 5.3.2 Contract Research Organizations
    • 5.3.3 Academic Institutions
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific
    • 6.1.2 Merck KGaA
    • 6.1.3 Agilent Technologies, Inc.
    • 6.1.4 Takara Bio Inc.
    • 6.1.5 New England Biolabs (UK) Ltd.
    • 6.1.6 HiMedia Laboratories
    • 6.1.7 Zymo Research
    • 6.1.8 Avantor
    • 6.1.9 TransGen Biotech Co., Ltd
    • 6.1.10 Scarab Genomics
    • 6.1.11 Lucigen Corporation
    • 6.1.12 Genscript Corporation
    • 6.1.13 Tonbo Biosciences
    • 6.1.14 Enzynomics co Ltd
    • 6.1.15 Klee GmbH
    • 6.1.16 NZYTech, Lda
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject To Availablity
**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Competent Cells Industry Segmentation

As per the scope of the report, competent cells are E.coli cells in which their cell walls are altered to allow easy incorporation of foreign DNA into the cells. Cells are made competent by either chemical or electrical means. Competent cells are used in cell transformation, cell cloning, and other cell engineering applications. The Competent Cells Market is segmented by Type (Chemically Competent Cells and Electrocompetent Cells), Application (Protein Expression, Cloning, Biotechnology, and Other Applications), End User (Biopharmaceutical Companies, Contract Research Organizations, and Academic Institutions), and Geography (North America, Asia-Pacific, Europe, Middle East, and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for all the above segments.

By Type Chemically Competent
Electrocompetent
By Application Protein Expression
Cloning
Biotechnology
Other Applications
By End User Biopharmaceutical Companies
Contract Research Organizations
Academic Institutions
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Competent Cells Market Research FAQs

The Competent Cells Market is projected to register a CAGR of 9.40% during the forecast period (2024-2029)

Thermo Fisher, Merck KGaA, New England Biolabs, Takara Bio and Agilent Technologies, Inc. are the major companies operating in the Competent Cells Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Competent Cells Market.

The report covers the Competent Cells Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Competent Cells Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Competent Cells Industry Report

Statistics for the 2024 Competent Cells market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Competent Cells analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Competent Cells Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)